Table 1.

Baseline patient demographics and characteristics

Anastrozole plus gefitinib (n = 43)Anastrozole plus placebo (n = 50)
Median age (range), y61 (41-82)58 (37-84)
WHO performance status, n (%)
    017 (40)31 (62)
    119 (44)17 (34)
    26 (14)1 (2)
Racial origin, n (%)
    Caucasian29 (67)29 (58)
    Black2 (5)4 (8)
    Other12 (28)17 (34)
ER status, n (%)*
    Positive38 (95)41 (85)
    Negative2 (5)3 (6)
    Unknown04 (8)
PgR receptor status, n (%)*
    Positive36 (90)30 (63)
    Negative4 (10)14 (29)
    Unknown04 (8)
Tumor grade, n (%)
    Well differentiated3 (7)1 (2)
    Moderately differentiated20 (47)21 (42)
    Poorly differentiated9 (21)17 (34)
    Not assessable9 (21)8 (16)
Recurrence site, n (%)
    Nodal axillary7 (16)13 (26)
    Skin4 (9)6 (12)
    Bone30 (70)37 (74)
    Lung14 (33)11 (22)
    Nodal (excluding axillary)14 (33)10 (20)
    Chest wall3 (7)5 (10)
    Liver8 (19)9 (18)
    Other9 (21)8 (16)

NOTE: One randomized patient not included as died before receiving treatment.

  • *Data from central laboratory (anastrozole plus gefitinib, n = 40; anastrozole plus placebo, n = 48).